Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism
Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents...
Gespeichert in:
Veröffentlicht in: | Leukemia 2008-06, Vol.22 (6), p.1191-1199 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1199 |
---|---|
container_issue | 6 |
container_start_page | 1191 |
container_title | Leukemia |
container_volume | 22 |
creator | Zhang, H Trachootham, D Lu, W Carew, J Giles, F J Keating, M J Arlinghaus, R B Huang, P |
description | Mutation of
Bcr-Abl
is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents capable of effectively killing CML cells with T315I mutation would have important therapeutic implications in Gleevec-resistant CML. Here, we showed that β-phenylethyl isothiocyanate (PEITC), a natural compound found in vegetables, is effective in killing CML cells expressing T315I BCR-ABL. Treatment of leukemia cell lines harboring wild-type or mutant
Bcr-Abl
with 10 μ
M
PEITC resulted in an elevated ROS stress and a redox-mediated degradation of the BCR-ABL protein, leading to massive death of the leukemia cells. Antioxidant NAC attenuated the PEITC-induced oxidative stress in CML cells and prevented the degradation of BCR-ABL, caspase-3 activation and cell death. We further showed that the ROS-induced degradation of BCR-ABL was mediated partially by caspase-3 and the proteasome pathway. The ability of PEITC to effectively kill T315I-positive CML cells was further confirmed using primary leukemia cells isolated from CML patients. Our results suggest that PEITC is a promising compound capable of killing Gleevec-resistant CML cells through a ROS-mediated mechanism and warrants further investigations. |
doi_str_mv | 10.1038/leu.2008.74 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2585768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A189833388</galeid><sourcerecordid>A189833388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c630t-e49eb9abc7f247ac13dd91dcb60ebb3545f6be567f42a25b5addea5d0d4956273</originalsourceid><addsrcrecordid>eNp1ks1v0zAYxiMEYmVw4o4sELtAiuOPfFyQpmqMSkVwKGfLcd40Hom92U5hR_5zHFptLRrywZLfn9_n8eM3SV5meJ5hWn7oYZwTjMt5wR4ls4wVeco5zx4nM1yWRZpXhJ0kz7y_wngq5k-Tk6ykJS84myW_L9oWVNBbQD9032uzQbZFlz3AFlTqwGsfpAlo8WWFFPS9Rz916NCaZnyJhjHIoK1B9S2SyMgwOtkjZYdrO5oGfbtYrhcodM6Omw45aOyvdIBGywANGkB10mg_PE-etLL38GK_nybfP12sF5_T1dfL5eJ8laqc4pACq6CuZK2KlrBCqow2TZU1qs4x1DXljLd5DTwvWkYk4TWXTQOSN7hhFc9JQU-Tj7u-12MdXSgwIboV104P0t0KK7U4rhjdiY3dCsJjVnkZG5ztGzh7M4IPYtB-ykQasKMXWcUpI3-V3vwDXtnRmfg4QXLGC1JGt5F6_V-KYE44PWy1kT0IbVobralJV5xnZVVSSsvJ2fwBKq4GBq2sgVbH86MLZwcXOpB96Lztx-kz_TH4bgcqZ7130N7llWExTZ-I0yem6RMFi_Srw4jv2f24ReDtHpBeyb510ijt7ziCGa04mWTf7zgfS2YD7j6bh3T_ANNi8F0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220525327</pqid></control><display><type>article</type><title>Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Nature Journals Online</source><source>SpringerLink Journals - AutoHoldings</source><creator>Zhang, H ; Trachootham, D ; Lu, W ; Carew, J ; Giles, F J ; Keating, M J ; Arlinghaus, R B ; Huang, P</creator><creatorcontrib>Zhang, H ; Trachootham, D ; Lu, W ; Carew, J ; Giles, F J ; Keating, M J ; Arlinghaus, R B ; Huang, P</creatorcontrib><description>Mutation of
Bcr-Abl
is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents capable of effectively killing CML cells with T315I mutation would have important therapeutic implications in Gleevec-resistant CML. Here, we showed that β-phenylethyl isothiocyanate (PEITC), a natural compound found in vegetables, is effective in killing CML cells expressing T315I BCR-ABL. Treatment of leukemia cell lines harboring wild-type or mutant
Bcr-Abl
with 10 μ
M
PEITC resulted in an elevated ROS stress and a redox-mediated degradation of the BCR-ABL protein, leading to massive death of the leukemia cells. Antioxidant NAC attenuated the PEITC-induced oxidative stress in CML cells and prevented the degradation of BCR-ABL, caspase-3 activation and cell death. We further showed that the ROS-induced degradation of BCR-ABL was mediated partially by caspase-3 and the proteasome pathway. The ability of PEITC to effectively kill T315I-positive CML cells was further confirmed using primary leukemia cells isolated from CML patients. Our results suggest that PEITC is a promising compound capable of killing Gleevec-resistant CML cells through a ROS-mediated mechanism and warrants further investigations.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/leu.2008.74</identifier><identifier>PMID: 18385754</identifier><identifier>CODEN: LEUKED</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Aldehyde Dehydrogenase - antagonists & inhibitors ; Animals ; Anticarcinogenic Agents - pharmacology ; Antineoplastic Agents - pharmacology ; Antioxidants ; Antioxidants - pharmacology ; Apoptosis - drug effects ; BCR-ABL protein ; Benzamides ; Biological and medical sciences ; Cancer Research ; Cancer therapies ; Caspase 3 - metabolism ; Caspase-3 ; Cell activation ; Cell death ; Cells, Cultured ; Chromosome aberrations ; Chronic myeloid leukemia ; Critical Care Medicine ; Cytotoxicity ; Degradation ; Dosage and administration ; Drug resistance ; Drug Resistance, Neoplasm ; Drug therapy ; Enzyme Activation - drug effects ; Fusion protein ; Fusion Proteins, bcr-abl - genetics ; Fusion Proteins, bcr-abl - metabolism ; Gene mutations ; Genetic aspects ; Glutathione - metabolism ; Health aspects ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Imatinib Mesylate ; Immunoblotting ; Inhibitor drugs ; Intensive ; Internal Medicine ; Isothiocyanate ; Isothiocyanates - therapeutic use ; Kinases ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical genetics ; Medical sciences ; Medicine ; Medicine & Public Health ; Mice ; Mutation ; Mutation - genetics ; Myeloid leukemia ; Oncology ; original-article ; Oxidation-Reduction ; Oxidative stress ; Piperazines - pharmacology ; Precursor Cells, B-Lymphoid - drug effects ; Precursor Cells, B-Lymphoid - metabolism ; Proteasomes ; Protein-tyrosine kinase ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Proteins ; Pyrimidines - pharmacology ; Reactive Oxygen Species - metabolism ; Targeted cancer therapy ; Thiocyanates ; Tumor cell lines</subject><ispartof>Leukemia, 2008-06, Vol.22 (6), p.1191-1199</ispartof><rights>Springer Nature Limited 2008</rights><rights>2008 INIST-CNRS</rights><rights>COPYRIGHT 2008 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jun 2008</rights><rights>Nature Publishing Group 2008.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c630t-e49eb9abc7f247ac13dd91dcb60ebb3545f6be567f42a25b5addea5d0d4956273</citedby><cites>FETCH-LOGICAL-c630t-e49eb9abc7f247ac13dd91dcb60ebb3545f6be567f42a25b5addea5d0d4956273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/leu.2008.74$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/leu.2008.74$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20439528$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18385754$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, H</creatorcontrib><creatorcontrib>Trachootham, D</creatorcontrib><creatorcontrib>Lu, W</creatorcontrib><creatorcontrib>Carew, J</creatorcontrib><creatorcontrib>Giles, F J</creatorcontrib><creatorcontrib>Keating, M J</creatorcontrib><creatorcontrib>Arlinghaus, R B</creatorcontrib><creatorcontrib>Huang, P</creatorcontrib><title>Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><description>Mutation of
Bcr-Abl
is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents capable of effectively killing CML cells with T315I mutation would have important therapeutic implications in Gleevec-resistant CML. Here, we showed that β-phenylethyl isothiocyanate (PEITC), a natural compound found in vegetables, is effective in killing CML cells expressing T315I BCR-ABL. Treatment of leukemia cell lines harboring wild-type or mutant
Bcr-Abl
with 10 μ
M
PEITC resulted in an elevated ROS stress and a redox-mediated degradation of the BCR-ABL protein, leading to massive death of the leukemia cells. Antioxidant NAC attenuated the PEITC-induced oxidative stress in CML cells and prevented the degradation of BCR-ABL, caspase-3 activation and cell death. We further showed that the ROS-induced degradation of BCR-ABL was mediated partially by caspase-3 and the proteasome pathway. The ability of PEITC to effectively kill T315I-positive CML cells was further confirmed using primary leukemia cells isolated from CML patients. Our results suggest that PEITC is a promising compound capable of killing Gleevec-resistant CML cells through a ROS-mediated mechanism and warrants further investigations.</description><subject>Aldehyde Dehydrogenase - antagonists & inhibitors</subject><subject>Animals</subject><subject>Anticarcinogenic Agents - pharmacology</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antioxidants</subject><subject>Antioxidants - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>BCR-ABL protein</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Caspase 3 - metabolism</subject><subject>Caspase-3</subject><subject>Cell activation</subject><subject>Cell death</subject><subject>Cells, Cultured</subject><subject>Chromosome aberrations</subject><subject>Chronic myeloid leukemia</subject><subject>Critical Care Medicine</subject><subject>Cytotoxicity</subject><subject>Degradation</subject><subject>Dosage and administration</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drug therapy</subject><subject>Enzyme Activation - drug effects</subject><subject>Fusion protein</subject><subject>Fusion Proteins, bcr-abl - genetics</subject><subject>Fusion Proteins, bcr-abl - metabolism</subject><subject>Gene mutations</subject><subject>Genetic aspects</subject><subject>Glutathione - metabolism</subject><subject>Health aspects</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Immunoblotting</subject><subject>Inhibitor drugs</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Isothiocyanate</subject><subject>Isothiocyanates - therapeutic use</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical genetics</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mice</subject><subject>Mutation</subject><subject>Mutation - genetics</subject><subject>Myeloid leukemia</subject><subject>Oncology</subject><subject>original-article</subject><subject>Oxidation-Reduction</subject><subject>Oxidative stress</subject><subject>Piperazines - pharmacology</subject><subject>Precursor Cells, B-Lymphoid - drug effects</subject><subject>Precursor Cells, B-Lymphoid - metabolism</subject><subject>Proteasomes</subject><subject>Protein-tyrosine kinase</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Proteins</subject><subject>Pyrimidines - pharmacology</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Targeted cancer therapy</subject><subject>Thiocyanates</subject><subject>Tumor cell lines</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1ks1v0zAYxiMEYmVw4o4sELtAiuOPfFyQpmqMSkVwKGfLcd40Hom92U5hR_5zHFptLRrywZLfn9_n8eM3SV5meJ5hWn7oYZwTjMt5wR4ls4wVeco5zx4nM1yWRZpXhJ0kz7y_wngq5k-Tk6ykJS84myW_L9oWVNBbQD9032uzQbZFlz3AFlTqwGsfpAlo8WWFFPS9Rz916NCaZnyJhjHIoK1B9S2SyMgwOtkjZYdrO5oGfbtYrhcodM6Omw45aOyvdIBGywANGkB10mg_PE-etLL38GK_nybfP12sF5_T1dfL5eJ8laqc4pACq6CuZK2KlrBCqow2TZU1qs4x1DXljLd5DTwvWkYk4TWXTQOSN7hhFc9JQU-Tj7u-12MdXSgwIboV104P0t0KK7U4rhjdiY3dCsJjVnkZG5ztGzh7M4IPYtB-ykQasKMXWcUpI3-V3vwDXtnRmfg4QXLGC1JGt5F6_V-KYE44PWy1kT0IbVobralJV5xnZVVSSsvJ2fwBKq4GBq2sgVbH86MLZwcXOpB96Lztx-kz_TH4bgcqZ7130N7llWExTZ-I0yem6RMFi_Srw4jv2f24ReDtHpBeyb510ijt7ziCGa04mWTf7zgfS2YD7j6bh3T_ANNi8F0</recordid><startdate>20080601</startdate><enddate>20080601</enddate><creator>Zhang, H</creator><creator>Trachootham, D</creator><creator>Lu, W</creator><creator>Carew, J</creator><creator>Giles, F J</creator><creator>Keating, M J</creator><creator>Arlinghaus, R B</creator><creator>Huang, P</creator><general>Nature Publishing Group UK</general><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>5PM</scope></search><sort><creationdate>20080601</creationdate><title>Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism</title><author>Zhang, H ; Trachootham, D ; Lu, W ; Carew, J ; Giles, F J ; Keating, M J ; Arlinghaus, R B ; Huang, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c630t-e49eb9abc7f247ac13dd91dcb60ebb3545f6be567f42a25b5addea5d0d4956273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aldehyde Dehydrogenase - antagonists & inhibitors</topic><topic>Animals</topic><topic>Anticarcinogenic Agents - pharmacology</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antioxidants</topic><topic>Antioxidants - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>BCR-ABL protein</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Caspase 3 - metabolism</topic><topic>Caspase-3</topic><topic>Cell activation</topic><topic>Cell death</topic><topic>Cells, Cultured</topic><topic>Chromosome aberrations</topic><topic>Chronic myeloid leukemia</topic><topic>Critical Care Medicine</topic><topic>Cytotoxicity</topic><topic>Degradation</topic><topic>Dosage and administration</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drug therapy</topic><topic>Enzyme Activation - drug effects</topic><topic>Fusion protein</topic><topic>Fusion Proteins, bcr-abl - genetics</topic><topic>Fusion Proteins, bcr-abl - metabolism</topic><topic>Gene mutations</topic><topic>Genetic aspects</topic><topic>Glutathione - metabolism</topic><topic>Health aspects</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Immunoblotting</topic><topic>Inhibitor drugs</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Isothiocyanate</topic><topic>Isothiocyanates - therapeutic use</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical genetics</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mice</topic><topic>Mutation</topic><topic>Mutation - genetics</topic><topic>Myeloid leukemia</topic><topic>Oncology</topic><topic>original-article</topic><topic>Oxidation-Reduction</topic><topic>Oxidative stress</topic><topic>Piperazines - pharmacology</topic><topic>Precursor Cells, B-Lymphoid - drug effects</topic><topic>Precursor Cells, B-Lymphoid - metabolism</topic><topic>Proteasomes</topic><topic>Protein-tyrosine kinase</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Proteins</topic><topic>Pyrimidines - pharmacology</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Targeted cancer therapy</topic><topic>Thiocyanates</topic><topic>Tumor cell lines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, H</creatorcontrib><creatorcontrib>Trachootham, D</creatorcontrib><creatorcontrib>Lu, W</creatorcontrib><creatorcontrib>Carew, J</creatorcontrib><creatorcontrib>Giles, F J</creatorcontrib><creatorcontrib>Keating, M J</creatorcontrib><creatorcontrib>Arlinghaus, R B</creatorcontrib><creatorcontrib>Huang, P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, H</au><au>Trachootham, D</au><au>Lu, W</au><au>Carew, J</au><au>Giles, F J</au><au>Keating, M J</au><au>Arlinghaus, R B</au><au>Huang, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2008-06-01</date><risdate>2008</risdate><volume>22</volume><issue>6</issue><spage>1191</spage><epage>1199</epage><pages>1191-1199</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><coden>LEUKED</coden><abstract>Mutation of
Bcr-Abl
is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents capable of effectively killing CML cells with T315I mutation would have important therapeutic implications in Gleevec-resistant CML. Here, we showed that β-phenylethyl isothiocyanate (PEITC), a natural compound found in vegetables, is effective in killing CML cells expressing T315I BCR-ABL. Treatment of leukemia cell lines harboring wild-type or mutant
Bcr-Abl
with 10 μ
M
PEITC resulted in an elevated ROS stress and a redox-mediated degradation of the BCR-ABL protein, leading to massive death of the leukemia cells. Antioxidant NAC attenuated the PEITC-induced oxidative stress in CML cells and prevented the degradation of BCR-ABL, caspase-3 activation and cell death. We further showed that the ROS-induced degradation of BCR-ABL was mediated partially by caspase-3 and the proteasome pathway. The ability of PEITC to effectively kill T315I-positive CML cells was further confirmed using primary leukemia cells isolated from CML patients. Our results suggest that PEITC is a promising compound capable of killing Gleevec-resistant CML cells through a ROS-mediated mechanism and warrants further investigations.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>18385754</pmid><doi>10.1038/leu.2008.74</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0887-6924 |
ispartof | Leukemia, 2008-06, Vol.22 (6), p.1191-1199 |
issn | 0887-6924 1476-5551 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2585768 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Nature Journals Online; SpringerLink Journals - AutoHoldings |
subjects | Aldehyde Dehydrogenase - antagonists & inhibitors Animals Anticarcinogenic Agents - pharmacology Antineoplastic Agents - pharmacology Antioxidants Antioxidants - pharmacology Apoptosis - drug effects BCR-ABL protein Benzamides Biological and medical sciences Cancer Research Cancer therapies Caspase 3 - metabolism Caspase-3 Cell activation Cell death Cells, Cultured Chromosome aberrations Chronic myeloid leukemia Critical Care Medicine Cytotoxicity Degradation Dosage and administration Drug resistance Drug Resistance, Neoplasm Drug therapy Enzyme Activation - drug effects Fusion protein Fusion Proteins, bcr-abl - genetics Fusion Proteins, bcr-abl - metabolism Gene mutations Genetic aspects Glutathione - metabolism Health aspects Hematologic and hematopoietic diseases Hematology Humans Imatinib Mesylate Immunoblotting Inhibitor drugs Intensive Internal Medicine Isothiocyanate Isothiocyanates - therapeutic use Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical genetics Medical sciences Medicine Medicine & Public Health Mice Mutation Mutation - genetics Myeloid leukemia Oncology original-article Oxidation-Reduction Oxidative stress Piperazines - pharmacology Precursor Cells, B-Lymphoid - drug effects Precursor Cells, B-Lymphoid - metabolism Proteasomes Protein-tyrosine kinase Protein-Tyrosine Kinases - antagonists & inhibitors Proteins Pyrimidines - pharmacology Reactive Oxygen Species - metabolism Targeted cancer therapy Thiocyanates Tumor cell lines |
title | Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T16%3A15%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effective%20killing%20of%20Gleevec-resistant%20CML%20cells%20with%20T315I%20mutation%20by%20a%20natural%20compound%20PEITC%20through%20redox-mediated%20mechanism&rft.jtitle=Leukemia&rft.au=Zhang,%20H&rft.date=2008-06-01&rft.volume=22&rft.issue=6&rft.spage=1191&rft.epage=1199&rft.pages=1191-1199&rft.issn=0887-6924&rft.eissn=1476-5551&rft.coden=LEUKED&rft_id=info:doi/10.1038/leu.2008.74&rft_dat=%3Cgale_pubme%3EA189833388%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220525327&rft_id=info:pmid/18385754&rft_galeid=A189833388&rfr_iscdi=true |